drugset / Trial / NCT00578682
A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557
RandomizedSingle-groupDouble-blindTreatment
Summary
To evaluate the safety and tolerability of a single IV dose of MEDI-557.
Timeline
- Start
- 2007-12
- Primary completion
- 2010-10
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI-557 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | MEDI-557 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | MEDI-557 | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | MEDI-557 | Monoclonal antibody | 30 mg/kg | Intravenous |
Indications
No indication recorded.